A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
← catalyst calendarNCT05629689 · readout in 934 d
Sponsored by GE Healthcare (industry) · GEHC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Diagnostic
Enrollment
50estimated
Sites
2
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-27 | actual | When the study began enrolling |
| Primary completion | 2029-03-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-10 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Malignant Solid Tumor
- Oncology
Interventions
- Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part A
- Diagnostic test: Dynamic and Static - PET/CT scan
- Drug: GEH200520 Injection / GEH200521 (18F) Injection - Part B
- Diagnostic test: Static - PET/CT scan
Primary outcomes
what the primary-completion date above is the date OFPart A: The incidence of AEs upon causality to the IMPs.
measured Part A: 7 days
Part A: The severity of AEs per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) upon causality to the IMPs.
measured Part A: 7 days
To evaluate the time-course changes in GEH200521 (18F) Injection uptake after immune-checkpoint inhibitor (ICI) treatment cycles compared to baseline.
measured Part B: 50 days
Permalink · GEHC's whole pipeline · Catalyst calendar · Every registered study · What changed